Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs

European Journal of Cancer

Volumn 49, Issue 17, 2013, Pages 3708-3717

  Tsubaki, Masanobu ^a   Komai, Makiko ^a   Itoh, Tatsuki ^b   Imano, Motohiro ^b   Sakamoto, Kotaro ^a   Shimaoka, Hirotaka ^a   Ogawa, Naoki ^a,c   Mashimo, Kenji ^a,d   Fujiwara, Daichiro ^a,d   Takeda, Tomoya ^a   Mukai, Junji ^c   Sakaguchi, Katsuhiko ^d   Satou, Takao ^b   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Izumi Municipal Hospital   (Japan)

^d JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

mTOR; Multiple myeloma; NF B; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; DEXAMETHASONE; DOXORUBICIN; FUMARIC ACID DIMETHYL ESTER; I KAPPA B; INFLIXIMAB; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; NEUTRALIZING ANTIBODY; PROTEIN BAX; RAPAMYCIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VINCRISTINE;

ARTICLE; BONE DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

MTOR; MULTIPLE MYELOMA; NF-ΚB; TNF-Α;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUMARATES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELPHALAN; MULTIPLE MYELOMA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886801821     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.07.010     Document Type: Article

References (36)

1. B. Klein, K. Tarte, and M. Jourdan Survival and proliferation factors of normal and malignant plasma cells Int J Hematol 78 2003 106 113
2. T. Hideshima, D. Chauhan, R. Schlossman, P. Richardson, and K.C. Anderson The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications Oncogene 20 2001 4519 4527
3. I. Kuku, M.R. Bayraktar, and E. Kaya Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma Mediators Inflamm 2005 3 2005 171 174
4. V.M. Lauta A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications Cancer 97 2003 2440 2452
5. L. Rosiñol, M.T. Cibeira, and M. Segarra Response to thalidomide in multiple myeloma: impact of angiogenic factors Cytokine 26 2004 145 148
6. H.I. Sati, M. Greaves, J.F. Apperley, R.G. Russell, and P.I. Croucher Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma Br J Haematol 104 1999 350 357
7. S. Ghosh, and M. Karin Missing pieces in the NF-kappaB puzzle Cell 109 Suppl. 2002 S81 S96
8. M. Thoh, P. Kumar, H.A. Nagarajaram, and S.K. Manna Azadirachtin interacts with the tumor necrosis factor (TNF) binding domain of its receptors and inhibits TNF-induced biological responses J Biol Chem 285 2010 5888 5895
9. M.K. Pandey, S.K. Sandur, and B. Sung Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue J Biol Chem 282 2007 17340 17350
10. M. Karin, Y. Cao, F.R. Greten, and Z.W. Li NF-kappaB in cancer: from innocent bystander to major culprit Nat Rev Cancer 2 2002 301 310
11. E.C. LaCasse, S. Baird, R.G. Korneluk, and A.E. MacKenzie The inhibitors of apoptosis (IAPs) and their emerging role in cancer Oncogene 17 1998 3247 3259
12. J.B. Almond, and G.M. Cohen The proteasome: a novel target for cancer chemotherapy Leukemia 16 2002 433 443
13. J.L. Luo, H. Kamata, and M. Karin IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy J Clin Invest 115 2005 2625 2632
14. H. Bark, and C.H. Choi PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-kappaB Cancer Chemother Pharmacol 65 2010 1131 1136
15. M. Bentires-Alj, V. Barbu, and M. Fillet NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells Oncogene 22 2003 90 97
16. X.Y. Pei, Y. Dai, and S. Grant Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors Clin Cancer Res 10 2004 3839 3852
17. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
18. S. Lonial Presentation and risk stratification - improving prognosis for patients with multiple myeloma Cancer Treat Rev 36 Suppl. 2 2010 S12 S17
19. M.A. Dimopoulos, and E. Terpos Multiple myeloma Ann Oncol 21 Suppl. 7 2010 vii143 vii150
20. A. Palumbo, M. Attal, and M. Roussel Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival Clin Cancer Res 17 2011 1253 1263
21. K. Blackwell, L. Zhang, and G.S. Thomas TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis Mol Cell Biol 29 2009 303 314
22. M.A. Rivas, R.P. Carnevale, and C.J. Proietti TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways Exp Cell Res 314 2008 509 529
23. D.F. Lee, H.P. Kuo, and C.T. Chen IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway Cell 130 2007 440 455
24. M.T. Kuo, Z. Liu, and Y. Wei Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling Oncogene 21 2002 1945 1954
25. A.M. Hunter, E.C. LaCasse, and R.G. Korneluk The inhibitors of apoptosis (IAPs) as cancer targets Apoptosis 12 2007 1543 1568
26. M. Wangpaichitr, C. Wu, and M. You Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins Eur J Pharmacol 591 2008 124 127
27. T. Shinjyo, R. Kuribara, and T. Inukai Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors Mol Cell Biol 21 2001 854 864
28. S. Shankar, S. Ganapathy, Q. Chen, and R.K. Srivastava Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis Mol Cancer 7 2008 16
29. A. Bauer, A. Villunger, and V. Labi The NF-kappaB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cells Proc Natl Acad Sci U S A 103 2006 10979 10984
30. F. Jundt, N. Raetzel, and C. Müller A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas Blood 106 2005 1801 1807
31. P. Rafiee, D.G. Binion, and M. Wellner Modulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B Am J Physiol Gastrointest Liver Physiol 298 2010 G865 G877
32. G.D. Roodman Pathogenesis of myeloma bone disease Blood Cells Mol Dis 32 2004 290 292
33. D. Christoulas, E. Terpos, and M.A. Dimopoulos Pathogenesis and management of myeloma bone disease Expert Rev Hematol 2 2009 385 398
34. G. Xu, K. Liu, and J. Anderson Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation Blood 119 2012 4205 4214
35. J. Pfeilschifter, C. Chenu, A. Bird, G.R. Mundy, and G.D. Roodman Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro J Bone Miner Res 4 1989 113 118
36. D. Lemancewicz, L. Bolkun, and E. Jablonska Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features Leuk Res. 37 2013 1089 1093